MMJ will Stay Marijuana Rescheduling? Why the D.C. Circuit Should Halt DEA's Schedule III Order - newswire.com
The D.C. Circuit is considering halting the DEA's order to reschedule marijuana to Schedule III, which could impact regulatory compliance for businesses in the pharmaceutical sector dealing with controlled substances.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Pharmaceutical manufacturers, particularly those involved with controlled substances. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No specific deadline provided; ongoing monitoring is necessary.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Potential delay in the rescheduling of marijuana to Schedule III, affecting compliance and regulatory frameworks.
Who it affects
Pharmaceutical manufacturers, particularly those involved with controlled substances.
What you must do
Monitor the D.C. Circuit's decision regarding the DEA's order and prepare for potential changes in compliance requirements.
Deadline
No specific deadline provided; ongoing monitoring is necessary.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Title V Synthetic Minor Permit Applications: STA Pharmaceutical - dnrec.delaware.gov
- Huons recalls three injectable exports in US over cGMP compliance issue - CHOSUNBIZ - Chosunbiz
- What FDA's AI Warning Letter Tells Us About GMP Accountability - pharmtech.com
- DEA Proposes Rescheduling DORAs - Sleep Review
- Supreme Court Rejection of Trump Tariffs Has Nuanced Implications for Pharma Importers - pharmtech.com